A peptide derived from hexokinase II selectively enters and kills cancer cells while delivering tumor-suppressor miR-126, with no toxicity to normal cells.
Cancer-selective, normal cells sparedPAS-pHK-miR-126 killed breast cancer MCF-7 cells but showed no toxicity to non-cancerous MCF-10A and HEK-293 cells
What the researchers found
PAS-pHK peptide delivers miR-126 selectively to cancer cells, targeting mitochondria to induce apoptosis synergistically while showing no toxicity to non-cancerous cells.
Why it matters
Selective cancer cell killing without harming normal cells is the holy grail of cancer therapy. This peptide-miRNA approach achieves selectivity by exploiting cancer-specific hexokinase II overexpression.
The numbers in context
PAS-pHK from N-terminal 15 amino acids of HKII; miR-126 synergistically enhanced anti-cancer effects; no toxicity to MCF-10A or HEK-93
How the study worked
In-vitro study designing a hexokinase II-derived CPP conjugated to miR-126 mimic, measuring cellular uptake, mitochondrial effects, ATP depletion, apoptosis, and selectivity in cancer vs. normal cell lines.
Who was studied
MCF-7 breast cancer cells, MCF-10A and HEK-93 normal cells
What this study cannot tell us
In-vitro only with limited cell line testing; no in-vivo tumor model; peptide stability in blood and biodistribution unknown; manufacturing of peptide-miRNA conjugates at scale not addressed.
How to read the evidence
Compelling in-vitro proof of concept with cancer selectivity demonstrated across multiple cell lines, but requires in-vivo validation.
When this study was published
Published in 2020; peptide-miRNA conjugates for selective cancer therapy remain an active research area.
The bigger picture
This combines two cancer-fighting strategies — metabolic disruption via mitochondrial targeting and gene silencing via miRNA delivery — into a single cancer-selective peptide conjugate.
Questions still open
- Does PAS-pHK-miR-126 show cancer selectivity and efficacy in animal tumor models?
- How does the conjugate perform in heterogeneous tumors with varying HKII expression?
- Can this platform deliver other therapeutic miRNAs beyond miR-126?
Common questions
Can peptides kill cancer cells selectively?
What is miR-126 and how does it fight cancer?
Read the original research
Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity.
Biochemistry, 59(24), 2259-2273
Citation
Palanikumar, L; Al-Hosani, Sumaya; Kalmouni, Mona; Saleh, Hadi Omar; Magzoub, Mazin. (2020). Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity.. Biochemistry, 59(24), 2259-2273. https://doi.org/10.1021/acs.biochem.0c00141